dr. hurvitz on standards of care in her2 breast cancer
Published 5 years ago • 169 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
1:39
dr. hurvitz on the lack of predictive biomarkers in her2 breast cancer
-
1:20
dr. hurvitz on the evolution of treatment in metastatic her2 breast cancer
-
1:58
dr. hurvitz discusses role of pertuzumab in her2 breast cancer
-
1:11
dr. hurvitz on importance of biosimilars in her2 breast cancer
-
2:00
her2 metastatic breast cancer: standard of care therapies
-
3:20
dr. hurvitz on eliminating anthracyclines in her2 breast cancer treatment
-
1:37
dr. hurvitz on how to navigate her2-targeted therapy in breast cancer
-
9:53
fibrosis biomarker: can it predict survival rates in her2-negative breast cancer?
-
2:01
dr. hurvitz on her2-targeted therapies in breast cancer
-
1:55
dr. hurvitz on novel emerging agents in her2 breast cancer
-
2:03
dr. hurvitz on novel agents in her2-positive breast cancer
-
1:00
dr. hurvitz on fda approval of subcutaneous trastuzumab formulation in her2 breast cancer
-
1:26
dr. hurvitz on unmet needs in her2 breast cancer
-
1:03
dr. hurvitz on the need for additional research with trastuzumab deruxtecan in her2 breast cancer
-
1:03
dr. hurvitz on steps to take with her2-positive breast cancer research
-
1:22
dr. hurvitz on the findings of destiny-breast01 in her2 metastatic breast cancer
-
1:41
dr. hurvitz on toxicity associated with neratinib in her2 breast cancer
-
1:35
dr. hurvitz on therapeutics for her2 metastatic breast cancer
-
0:58
dr. hurvitz on treatment options for her2-positive breast cancer